title: Mutation analysis of BRCA1 and BRCA2 cancer predisposition genes in radiation hypersensitive cancer patients.
abstract: OBJECTIVE
  The dose intensity of radiotherapy (RT) used in cancer treatment is limited in rare individuals who display severe normal tissue reactions after standard RT treatments. Novel predictive assays are required to identify these individuals prior to treatment. The mechanisms responsible for such reactions are unknown, but may involve dysfunction of genes involved in the sensing and response of cells to DNA damage. The breast cancer susceptibility genes BRCA1 and BRCA2 are implicated in DNA damage repair and the control of genome stability. The purpose of this study was to determine if clinical radiation hypersensitivity is related to mutations of the BRCA1 and BRCA2 genes. Such information is of potential use in the clinical management of BRCA mutation carriers and their families.
  
  
  METHODS
  Twenty-two cancer patients who developed severe normal tissue reactions after RT were screened for mutations of BRCA1 and BRCA2, using various methods including protein truncation testing, direct DNA sequencing, and a PCR-based BRCA1 exon 13 duplication test.
  
  
  RESULTS
  No mutations were detected in the 22 patients tested, despite screening for the majority of commonly described types of mutations of BRCA1 and BRCA2.
  
  
  CONCLUSIONS
  These early results suggest that genes other than BRCA1 and BRCA2 probably account for most cases of clinical radiation hypersensitivity, and that screening for mutations of BRCA1 and BRCA2 is unlikely to be useful in predicting response to radiotherapy. However, it has not been excluded that some BRCA1 or BRCA2 heterozygotes might experience unexpected RT toxicity; further BRCA mutation screening on radiation sensitive individuals is warranted.
authors.affiliation: Division of Radiation Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia.
authors.forename: T
authors.initials: T
authors.lastname: Leong
authors.forename: J
authors.initials: J
authors.lastname: Whitty
authors.forename: M
authors.initials: M
authors.lastname: Keilar
authors.forename: S
authors.initials: S
authors.lastname: Mifsud
authors.forename: J
authors.initials: J
authors.lastname: Ramsay
authors.forename: G
authors.initials: G
authors.lastname: Birrell
authors.forename: D
authors.initials: D
authors.lastname: Venter
authors.forename: M
authors.initials: M
authors.lastname: Southey
authors.forename: M
authors.initials: M
authors.lastname: McKay
mesh_terms: D024682:BRCA2 Protein; D001943:Breast Neoplasms / Q000235:genetics* / Q000532:radiotherapy; D004252:DNA Mutational Analysis / Q000379:methods; D005260:Female; D019398:Genes, BRCA1 / Q000235:genetics*; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D006801:Humans; D009154:Mutation; D009363:Neoplasm Proteins / Q000235:genetics*; D011836:Radiation Tolerance / Q000235:genetics; D014157:Transcription Factors / Q000235:genetics*
chemical_list: D024682:BRCA2 Protein; D009363:Neoplasm Proteins; D014157:Transcription Factors